last year, while gross profit margin was slightly strengthened from 6.83% in 1H/2016 to 7.89% in 1H/2017. Other income in 1H/2017 amounted to Baht 741.35 million, a surge by Baht 375.49 million or 102.63
/11/2001 01/01/2002 Report/Form (Notification of Securities and Exchange Commission) Form OrYo.1 Petition for the Dispute Report/Form (Notification of Securities and Exchange Commission) Form OrYo.2
/11/2001 01/01/2002 Report/Form (Notification of Securities and Exchange Commission) Form OrYo.1 Petition for the Dispute Report/Form (Notification of Securities and Exchange Commission) Form OrYo.2
, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
to May 15, 2019. Since GSTEL had filed the rehabilitation petition to the Central Bankruptcy Court on November 14, 2017 as disclosed to the Stock Exchange of Thailand (SET), GSTEL was unable to repay
extinguish. In contrast, in case of the failure to make the payment in full, the SEC shall file a petition with a civil court for enforcement in accordance with the letter of consent. On the other hand, where
related corporate tax transaction, the normalized net profit would be approximately THB 97.42 million or a surge of 48% yoy. Page 3 of 4 Statement of Financial Position as of March 31, 2019 The consolidated
March 2018 increased by 19% yoy mainly from the surge of provisions for employee benefit and other liabilities. Most of the increase of other liabilities was income tax payable on 2017 profit because
on December 31, 2018). The Company extended the loan tenor from November 15, 2017 to May 15, 2019. Since GSTEL had filed the rehabilitation petition to the Central Bankruptcy Court on November 14, 2017
judgment. Moreover, the plaintiff and the Company are currently filing the petition to the Supreme Court. At present, the Company has recorded interest expenses for the year 2018 at the rate of 8.50% per